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The 4th annual international RNAi conference at Oxford, 
RNAi2009: Bridging Biology and Therapy, was held at St 
Anne’s college, Oxford, UK (18-19
th March). The meeting 
attracted a wide range of participants from both academic 
and  industrial  backgrounds  to  assemble  and  disseminate, 
discuss and debate advances within the rapidly moving field 
of RNAi. There was a spectrum of experts, both national 
and international, who covered a range of stimulating RNAi 
topics. A selection of research posters was also on display 
for the duration of the conference.  Conference participants 
were  given  the  opportunity  to  learn  about  the  latest 
commercial products at the trade exhibition, which featured 
Thermo  Scientific,  Qiagen,  Eurogentec,  Integrated  DNA 
Technologies, Pfizer-Coley, Exiqon, Agilent Technologies 
and Oxford University Press. 
 
miRNAS  IN  IMMUNITY,  DISEASE  AND 
DEVELOPMENT 
 
When the immune system is activated by pathogens the 
Toll-like and IL-1 receptors effect rapid stimulation of a 
variety  of  genes.  Research  is  underway  to  delineate  the 
role of miRNAs in this process. Mark Lindsay (University 
of Manchester, UK) presented results on the role of miR-
146a and miR-155 during an IL-1β-induced inflammatory 
response in alveolar cells. 
 
Marcus Peter (University of Chicago, US) addressed the 
role of miRNAs in tumour progression using a panel of 60 
cancer cell lines. Genetic analysis shows the lines can be 
broadly  divided  into  two  groups,  representing  early  and 
late  stages  of  tumour  development.  Work  in  Dr  Peter’s 
laboratory  has  identified  key  differences  in  miRNA 
expression that may underpin the phenotypic differences 
between the two cell types, and thus cancer progression. 
For  example,  the  miRNA  let-7  was  shown  to  correlate 
with  cell  types  bearing  an  epithelial  gene  expression 
profile. A second miRNA family, miR-200, was identified 
that regulates Vimentin and E-Cadherin, two genes whose 
expression  is  often  lost  during  cancer  progression.  The 
miR-200 family, which is up-regulated in the epithelial-
like  cancer  lines,  appears  to  inhibit  Vimentin  and  E-
Cadherin expression by targeting two transcription factors 
involved in their normal activation, ZEB1 and ZEB2 (Park 
et al, 2008). 
 
Enrico  De  Smaele  (University  of  Rome,  Italy)  also 
described how miRNA expression analysis has emerged as 
a powerful tool for identifying new important molecules 
involved in malignancies. Application of this technique to 
medulloblastoma  carcinomas  identified  patterns  of 
miRNA  expression  that  correlate  with  cancer  histotypes 
(anaplastic, classic and desmoplastic) and with  molecular 
features  (such  as  over-expression  of  ErbB2  or  c-Myc) 
(Ferretti  et  al,  2009).  Identification  of  deregulated 
miRNAs in cancer progression should provide diagnostic 
biomarkers  and  potential  targets  for  new  therapeutic 
strategies. 
 
The mechanisms that regulate activity of specific miRNAs 
during development remain largely unexplored. Youn-Bok 
Lee (University of Bristol, UK) analysed the interaction of 
transcription  factors  with  miRNAs  during  mouse 
development.  The  results  showed  that  Twist-1,  a  basic 
helix-loop-helix transcription factor, activates transcription 
of miR-199a and miR-214 in neural cells. 
 
IN VITRO AND IN VIVO DELIVERY OF NUCLEIC 
ACID THERAPEUTICS 
 
Despite the power and potential of RNAi as a therapeutic 
technique, a therapy is only as good as its delivery system. 
There are two key considerations with a delivery system, 
the  identification  of  an  optimal  route  of  administration, 
and establishing efficient cellular uptake and intracellular 
release of the nucleic acids.  
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Dmitry  Samarsky  (RXi  Pharmaceuticals,  US)  presented 
potential  systems  for  delivery  of  rxRNA  silencing 
compounds, that exhibit reduced immune stimulation and 
high potency. Jörg Vollmer (Pfizer Coley, Germany) and 
Achim  Algner  (Phillips-University  School  of  Medicine, 
Germany) also presented their work on delivery systems 
that  reduce  toxicity  in  vivo.  Cy  Stein  (Albert  Einstein 
College of Medicine, US) described a remarkable system 
for the insertion of antisense oligonucleotides into cells, 
termed  Gymnotic  delivery.  Cells  were  thought  to  be 
impermeable  to  polyanions  such  as  oligonucleotides, 
necessitating  the  use  of  chemical  carriers.  Efficient 
Gymnotic  delivery  of  an  antisense  oligo  against  Bcl-2 
depends  on  the  cell  plating  density  used  and  prolonged 
treatment  over  six  days,  and  results  in  more  than  90% 
silencing at the mRNA and protein level. Georg Sczakiel 
(Lübeck  University,  Germany)  also  demonstrated  the 
uptake  of  naked  oligonucleotides  into  human  cells 
stimulated  with  phosphorothioate.  This  mechanism 
delivered  a  large  amount  of  siRNA  and  made  use  of  a 
caveosomal instead of an enodsomal pathway. 
 
For siRNAs to be effective they not only require efficient 
uptake  into  cells,  but  must  also  be  released  from  the 
endosomes  that  internalise  them.  Raymond  Schiffelers 
(Utrecht  University,  the  Netherlands)  described  a 
technique  called  photochemical  internalisation  (PCI)  for 
the  in  vivo  release  of  siRNA  from  endosomes.  A431 
tumour cells were injected with a photosensitive chemical 
and siRNA lipoplexes against EGFR. Exposure of these 
cells  to  light  increased  EGFR  silencing  efficiency  by 
150%  (compared  to  cells  not  exposed  to  light), 
demonstrating  the  potential  of  this  technique  in  cancer 
therapy (Oliveira et al, 2007). 
 
RNAi AND VIRUSES 
 
A wide range of miRNAs have been identified in plants, 
mammals and viruses.  Viral miRNAs appear to modify 
viral and host gene expression. Venugopal Nair (Institute 
for  Animal  Health,  UK)  highlighted  this  in  strains  of 
herpesviruses that cause Marek’s disease, a rapid-onset T-
cell  lymphoma,  in  poultry.  Dr  Nair’s  team  identified  a 
group  of  highly  expressed  viral  miRNAs  that  appear  to 
play a role in pathogenesis (Yao et al, 2008). 
 
Lars  Dölken  (Ludwig  Maximilians-University  Munich, 
Germany)  described  the  identification  of  18  distinct 
miRNAs  from  the  murine  cytomegalovirus  (MCMV).  
Analysis of RNA levels during infection of fibroblast cells 
suggests  a  highly  regulated  program  of  viral  miRNA 
expression (Dölken et al, 2007). Nikolaus Machuy (Max-
Planck-Institute,  Germany)  demonstrated  the  power  of 
RNAi  to  identify  genes  involved  in  the  influenza  virus 
life-cycle. 
 
RNAi  has  also  been  proposed  as  a  potential  therapy 
against viruses, including HIV. Ben Berkhout (University 
of Amsterdam, the Netherlands) demonstrated this in vitro 
using RNAi to effectively  silence essential  genes in the 
HIV genome, resulting in abolished viral proliferation (ter 
Brake et al, 2008). However, the virus shows a remarkable 
ability  to  escape  the  inhibition,  often  through  mutations 
that  alter  DNA  sequence  without  altering  amino  acid 
usage. Dr Berkhout’s exciting results show that inhibition 
escape can be prevented if at least four different regions 
are simultaneously targeted by RNAi, offering hope for a 
new HIV therapy. 
 
TECHNOLOGY FOCUS 
 
The  fast  pace  within  the  field  of  RNAi  means  that  the 
technology involved has to be dynamic, adaptable and up 
to date.  Speakers covered a range of advancements in the 
currently available technology.  These included synthetic 
miRNA inhibitors, mimics and improvements in biological 
activity and nuclease resistance. 
 
Martin Kreutz (Qiagen, Germany) presented information 
on the miScript system, which enables the detection and 
quantification  of  small  non-coding  RNAs,  including 
miRNAs and piRNAs. This was used in combination with 
a range of miRNA mimics to study the expression pattern 
and function of miRNAs during T-cell activation in Jurkat 
cells.  Stephanie  Urschel  (Thermo  Scientific,  Germany) 
also  described  a  range  of  products  to  analyse  miRNA 
expression and function during osteoblast differentiation. 
 
Natal’ya Kruglova (Institute of Chemical Biological and 
Fundamental  Medicine,  Russia)  used  2’-O-methyl 
analogues  at  sites  in  siRNAs  predicted  to  suffer  from 
nuclease sensitivity. Modification at these sites increased 
nuclease  resistance,  resulting  in  a  prolonged  silencing 
effect  compared  to  unmodified  controls  (Volkov  et  al, 
2009). Tatiana Kabilova (Institute of Chemical Biological 
and Fundamental Medicine, Russia) described how siRNA 
structure  can  influence  non-specific  biological  effects, 
such as immune stimulation. 
 
Mark  Behlke  (Integrated  DNA  technologies,  USA) 
presented a novel method to silence gene expression which 
does not rely on RNAi or antisense oligos. The technique 
involves the use of bimodular oligonucleotides, known as 
U1  adaptors,  which  tether  the  U1  small  nuclear 
ribonucleoprotein splicing factor to the terminal exon of 
the target gene. This results in impaired polyadenylation of 
the target and subsequent RNA degradation (Goraczniak et 
al, 2009). The synthetic U1 adaptors direct specific down-
regulation of target genes with few off-target effects, and 
when combined with siRNAs result in even greater levels 
of gene knock-down. 
 
INTERFERING  RNAS:  BIOLOGY,  DISEASE  AND 
DEVELOPMENT 
 
A  broad  range  of  potential  RNAi  applications  were 
presented,  ranging  from  the  identification  of  drug 
biomarkers to the role of RNAi in the autoregulation of 
heterochromatin.  Zubair Ahmed (University Birmingham, 
UK)  used  RNAi  to  dissect  the  pathways  involved  in 
apoptosis  following  optic  nerve  damage.  The  results 
suggest a potential therapy to prevent nerve cell loss and 
promote cell regeneration following injury to optic nerves. 
 
Leukaemia  progression  often  involves  chromosomal 
translocations  that  remove  oncogenes  from  their  normal  
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chromatin environment, leading to inappropriate activation. 
In  certain  cases  the  translocation  results  in  a  fusion  of 
oncogenes.  Olaf  Heidenreich  (Newcastle  University,  UK) 
proposed  that  these  fusion  proteins  provide  unique 
therapeutic  targets,  and  showed  evidence  that  siRNAs 
designed  to  straddle  the  fusion  site  can  specifically  knock 
down the aberrant proteins (Thomas et al, 2006). 
 
Nick Proudfoot (University of Oxford, UK) described the 
auto-regulation  of  convergent  genes  by  transient 
heterochromatin  formation  in  S.  pombe.  During  the  G1 
phase of the cell cycle double-stranded RNA is generated 
that  leads  to  RNAi-mediated  heterochromatin  formation 
across convergent genes. Cohesin, a protein involved in 
chromosome  dynamics,  binds  chromatin  between  the 
convergent  genes  in  G2  phase,  preventing  dsRNA 
formation (and the subsequent heterochromatin formation) 
and  relieving  the  gene  repression  (Gullerova  and 
Proudfoot, 2008). This remarkable mechanism of transient 
heterochromatin  formation  further  demonstrates  the 
breadth and power of RNAi. 
 
Cancerous  growths  within  any  given  tissue  can  arise 
through  a  variety  of  mechanisms.  This  heterogeneity 
hinders our efforts to develop appropriate treatments and 
means that patients respond differently to specific drugs. 
Identifying biomarkers that correlate with drug resistance 
should lead to improvements in patient management. René 
Bernards (Netherlands Cancer institute, the Netherlands) 
used  RNAi  to  knock  down  over  8,000  human  genes  in 
breast cancer cells and identify genes conferring resistance 
to  Herceptin  treatment.  This  loss-of-function  assay 
implicated  genes  of  the  PI3  Kinase  pathway  in  the 
resistance to this breast cancer drug (Berns et al, 2007). 
The  technique  is  now  being  extended  to  study  the 
mechanistic basis of resistance to a range of drugs. 
 
CONCLUDING REMARKS 
 
The conference gave the RNAi community the opportunity 
to present and discuss advances that have occurred over 
last twelve months. Research presented at this conference 
highlighted  the  increasing  momentum  that  RNAi  is 
gaining; a field which was in its infancy at the beginning 
of  the  decade.  Whilst  a  number  of  technical  challenges 
remain to be conquered, we surely stand at the cusp of a 
revolution in the way that diseases like cancer and HIV are 
treated.  The  next  decade,  and  indeed  the  next  twelve 
months, should be very exciting for the field of RNAi. 
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